|
|||||||||||||||||||||
|
|||||||||||||||||||||
HUM-MOLGEN -> biomedical companies | search | registration | modification | |||||||||||||||||||||
registry of biomedical companies |
|||||||||||||||||||||
December 28, 2024 |
promoting the transfer of scientific know-how between industry and academia |
||||||||||||||||||||
Since the first day, GenScript believed that "human and science engines" were the driving forces of its business. That is why among its 2600+ employees, by now there are more than 800 with masters or Ph.D. degrees. This percentage is even higher than 90% in R&D and commercial teams. These powerful engines have enabled GenScript to develop and use the latest discoveries and technologies for establishing its fully integrated platforms towards generating industry-leading, highly customizable reagents for diverse applications. GenScript's dedication to innovation and quality, with outstanding products and quality services, excellent reputation, and a comprehensive portfolio of patents and trade secrets in synthetic biology, chemicals synthesis, protein and antibody engineering, immunotherapy and bioinformatics, GenScript has created a leading edge in the industry as well as close relationships with investors, such as KPCB, Shipston Group, China Resources and BALLOCH. Has helped to establish strong partnerships with customers in over 60 countries. GenScript’s current client list includes all of the top 20 pharmaceutical companies in the world. However, its technological achievements are complemented by its customer service. Every project, irrespective of size, gets top treatment at GenScript. Moving strongly into the future, GenScript continues to strive for its vision as the most reliable biotech company in the world to make people and nature healthier. Selected Categories:
Last update of this entry: August 20, 2019
|
|||||||||||||||||||||
|
|||||||||||||||||||||
Generated by companies 4.0 by Kai Garlipp |